Source comparison
Best ARA-290 Dosage for Sarcoidosis: Protocol Comparison
Sarcoidosis-SFN Phase 2 4 3× weekly (SC) 28 days Neuropathic pain reduction (VAS) The Lancet 2014 Diabetic Neuropathy Phase 2 2 12 weeks IENFD improvement, corneal nerve density Diabetes Care 2015 Extended Neuropathy Study 24 weeks Long-term pain scores, QOL m
This comparison does not assign a generated winner or score.
- Sarcoidosis-SFN Phase 2
- 4
- 3× weekly (SC)
- 28 days
- Neuropathic pain reduction (VAS)
- The Lancet 2014
- Diabetic Neuropathy Phase 2
- 2
- 12 weeks
- IENFD improvement, corneal nerve density
- Diabetes Care 2015
- Extended Neuropathy Study
- 24 weeks
- Long-term pain scores, QOL metrics
- Pain Medicine 2017
- Low-Dose Exploratory
- 1
- 8 weeks
- Safety, preliminary pain reduction
- Unpublished pilot
- Professional Assessment
- 1–4mg three times weekly appears optimal for small fiber neuropathy outcomes; higher doses (6–8mg) tested in diabetes showed no additional benefit, suggesting receptor saturation below 4mg. Duration should match endpoint. 4 weeks minimum for subjective pain, 12 weeks for objective nerve density.